# DESCRIPTION

## BACKGROUND OF THE DISCLOSURE

- describe inflammatory bowel disease
- highlight limitations of current diagnosis

## SUMMARY

- introduce DEFA5 biomarker
- describe method of measuring DEFA5
- outline methods of treating IBD
- summarize kit for measuring DEFA5

## DETAILED DESCRIPTION

- define terms and conventions
- describe DEFA5 protein and its functions
- introduce anti-DEFA5 antibody and its properties
- describe high affinity anti-DEFA5 antibody
- explain high specificity anti-DEFA5 antibody
- provide examples of commercially available anti-DEFA5 antibodies
- describe method of diagnosing ulcerative colitis or Crohn's disease
- explain measuring DEFA5 levels or expression in a sample
- describe symptoms of IBD
- discuss DEFA5 as a biomarker for distinguishing UC and CD
- describe treatment options based on DEFA5 levels or expression
- introduce complementarity determining region (CDR) of anti-DEFA5 antibody
- describe antibody having a certain degree of identity to a polypeptide sequence
- illustrate specificity of commercially available DEFA5 antibodies
- discuss potential mechanism of inflammation in patients with CD
- explain potential consequences of excessive inactive form DEFA5
- define DEFA5 benchmark value
- establish benchmark by analysis of control sample
- describe assay method for differentially diagnosing UC and CD
- measure DEFA5 expression by ELISA
- diagnose UC or CD based on DEFA5 expression level
- describe alternative assay methods
- measure DEFA5 activity and/or expression
- determine disease states and conditions associated with DEFA5 activity
- describe treatment methods for UC
- describe treatment methods for CD
- perform intervention based on DEFA5 expression level
- provide kit for measuring DEFA5
- illustrate specificity of DEFA5 antibodies
- illustrate alignment of DEFA5 with HD1 and HD6
- illustrate sandwich ELISA for detecting pro-DEFA5 and mature DEFA5
- illustrate problem of diagnostic uncertainty in IBD clinical setting
- show DEFA5 levels can be used to determine patient candidacy for IPAA
- illustrate histological staining for Paneth cell markers
- illustrate H&E staining for Paneth cell markers
- illustrate double stain of PCs, Lysosomes and DEFA5
- illustrate image deconvolutions for lysozyme and DEFA5

### Working Example 1

- introduce DEFA5 antibodies
- describe inability to distinguish CC from UC
- perform preliminary assessment of DEFA5 expression
- collect clinical samples
- perform retrospective studies on IBD patients
- identify genes differentially expressed in UC vs. CC
- validate DEFA5 expression by semi-quantitative RT-PCR
- detect DEFA5 by western blotting
- examine DEFA5 expression by IHC
- quantify DEFA5 IHC staining
- detect DEFA5 in IBD colectomy tissues
- evaluate DEFA5 as a diagnostic tool for CC

### Prophetic Example 2

- establish specificity and selectivity of DEFA5 antibodies
- evaluate commercially available DEFA5 antibodies
- identify DEFA5 specific antibodies
- detect DEFA5 in sera from IBD patients and normal subjects
- optimize DEFA5 sandwich ELISA
- detect DEFA5 expression in FFPE IBD biopsies/tissues by IHC
- determine correlation between DEFA5 levels in colonic mucosa tissues and circulating levels

### Working Example 3

- introduce Paneth cells and their role in IBD
- motivate research on DEFA5 and pro-inflammatory cytokines
- describe experimental design to test hypothesis
- present results of IHC staining and DEFA5 detection
- discuss implications of findings on CC and UC
- provide general disclaimer on embodiments and scope of invention

